The antimicrobial activity of cinoxacin, 1-ethyl-4(1H)-oxo- [1, 3] dioxolo [4,5-g]cinnoline-3-carboxylic acid, previously reported as compound 64716, was determined and compared with other antimicrobial agents at a dosage of 12 mg/kg once daily in a descending pyelonephritis rat model with Escherichia coli and Proteus mirabilis as infecting organisms. Cinoxacin was considerably more effective than either nalidixic acid or oxolinic acid when all three were administered orally at 3 mg/kg four times daily. (BBL), suspended in brain heart infusion broth (BBL), divided into 0.2-ml portions, and frozen in liquid nitrogen. Bacterial suspensions for rat inoculations were prepared daily by seeding a 50-ml flask of brain heart infusion broth from a frozen ampoule and growing the culture ovemight at 37 C on a shaker. The E. coli culture was diluted to 5 x 108 colony-forming units per ml, and the P. mirabilis culture was diluted to 1 x 101 colony-forming units per ml.
ported as compound 64716, possesses excellent in vitro activity against gram-negative bacteria that are frequently encountered in urinary tract infections (5) . This compound was also effective in therapy of experimental infections in mice caused by susceptible organisms. However, the mouse therapy experiments, which are evaluated using survivor-death end points, did not allow full assessment of differences in pharmacological properties of cinoxacin from those of other synthetic antibacterial agents. For this reason, an experimental descending pyelonephritis infection in rats was adopted. The data presented in this report permit a comparison of the efficacy of cinoxacin with that of other antimicrobial agents against Esch (BBL) , suspended in brain heart infusion broth (BBL), divided into 0.2-ml portions, and frozen in liquid nitrogen. Bacterial suspensions for rat inoculations were prepared daily by seeding a 50-ml flask of brain heart infusion broth from a frozen ampoule and growing the culture ovemight at 37 C on a shaker. The E. coli culture was diluted to 5 x 108 colony-forming units per ml, and the P. mirabilis culture was diluted to 1 x 101 colony-forming units per ml.
Antimicrobial agents. Cinoxacin, cephaloridine, cefazolin, tobramycin, and cephaloglycin were prepared in the Lilly Research Laboratories. Other agents employed and their sources were: carbenicillin indanyl sodium, Pfizer, Inc.; disodium carbenicillin, J. B. Roerig, Division of Pfizer, Inc.; gentamicin sulfate, Schering Corp.; sodium ampicillin, Bristol Laboratories, Division of Bristol-Myers Co.; nitrofurantoin, Eaton Laboratories, Division of MortonNorwich Products, Inc.; nalidixic acid, Winthrop Laboratories, Division of Sterling Drug, Inc.; oxolinic acid, Warner-Lambert Research Institute; and trimethoprim-sulfamethoxazole (1:5), Roche Laboratories, Division of Hoffman-LaRoche, Inc. Certain of the antimicrobial compounds were administered by gavage once, twice, or four times daily for 7 days, and others were injected subcutaneously. All compounds were suspended in 0.125% carboxymethylcellulose.
Experimental rat infections. Female, randombred albino rats (Cox-Wistar) weighing 190 to 210 g were anesthetized by intraperitoneal injection of 12 mg of sodium methohexital supplemented as necessary. The experimental pyelonephritis model was based on the studies of Guze and Beeson in which the left ureter was occluded for 20 min, followed by injection of 0.5 ml of the test organism in the femoral vein (4) . Antimicrobial therapy commenced 4 to 5 h postinfection except where otherwise noted. Four hours after the last treatment the rats were sacrificed, and the left kidney was removed and homogenized in a Duall grinder containing 9 ml of physiological saline. This represented a 10-1 dilution of the kidney tissue. Additional 10-fold dilutions in saline were based on the anticipated bacterial cells present in the tissue homogenate. Finally, duplicate agar pour plates were made from several of these dilutions, and the plates were incubated overnight at 37 C. The therapeutic results were expressed in two ways: (i) the percentage of rats with kidney counts of less than 102 per g of kidney tissue, referred to as "cures," and (ii) the percentage of rats with at least a 4-log10 reduction in bacterial titer compared with infected control kidneys. Control rats were treated with 0.125% carboxymethylcellulose only. Viable cell counts in kidney tissue from control rats with either E. coli or P. mirabilis infections ranged from 1.2 x 10' to 4.6 x 108 per g of homogenized tissue. Most experiments were replicated at least three times.
In vitro susceptibility tests. Minimal inhibitory concentrations for all of the antimicrobial agents against E. coli and P. mirabilis were determined by broth or agar dilution procedures (5) .
Concentrations of antimicrobial agents in rat urine and serum. Groups of six rats housed in metabolic cages were given one dose of 3 mg/kg orally, and their urine was collected over a 24-h period. Determinations of antimicrobial activity of cinoxacin, oxolinic acid, and nalidixic acid excreted in urine were performed by a disk plate method (5) . The minimal sensitivity of this assay is 5 ug/ml for cinoxacin and nalidixic acid and 1.0 jsg/ml for oxolinic acid. The method of assay for trimethoprim-sulfamethoxazole (TMP-SMZ) and nitrofurantoin was similar to the above assay tech:nique, but Mueller-Hinton agar and an E. coli overnight culture diluted 1:10 was used. Sensitivity of this assay is 1.25 Ag/ml for TMP-SMZ and 25 ug/ml for nitrofurantoin.
Blood serum concentrations were determined from rats given one oral dose of cinoxacin. The level of cinoxacin in rat sera was determined by high-pressure ion-exchange chromatography with anion exchange resins similar to a chromatographic procedure described previously (1) .
RESULTS AND DISCUSSION
The in vitro susceptibility of E. coli 028 and P. mirabilis 8897 to 13 antimicrobial agents is shown in Table 1 . Both microorganisms appeared susceptible in vitro to all of the antimicrobials used in this study.
Twelve antimicrobial agents were compared with cinoxacin in the descending rat pyelonephritis infection ( Fig. 1 and 2 ). Usually 10 rats were used for each drug level and 10 rats were used as controls. A single daily oral treatment with cinoxacin at 12 mg/kg cured 46% and reduced the kidney counts by 4 log10 or greater in 53% of the E. coli-infected rats (Fig. 1) cefazolin, tobramycin, and gentamicin administered subcutaneously were very effective against the E. coli infection. Using a similar descending pyelonephritis model, another investigator found that nalidixic acid reduced E. coli titers in kidneys 2 log10, and nitrofurantoin reduced titers 4 log1o when 50 or 100 mg/kg was administered once daily (2) .
One oral daily treatment (Fig. 2 ) of cinoxacin at 12 mg/kg cured 53% and reduced the kidney counts by 4 logl1 or greater in 65% of the P. mirabilis-infected rats. Nitrofurantoin at the same dosage level cured and reduced kidney counts by 4 logl0 in 21% of the rats; nalidixic acid cured 43% with 4-log10 reduction of 60%, and TMP-SMZ cured and reduced kidney counts by 4 log1,0 in 44%. Cures with 12 mg/kg of oxolinic acid were as low at 13%, but 4-log10 reduction was 48%. Ampicillin administered orally and cephaloridine, cefazolin, tobramycin, gentamicin, and carbenicillin administered subcutaneously were the most active agents in this infection.
Previous studies indicated that 100 or 200 mg of cephaloglycin per kg administered orally was ineffective against E. coli rat pyelonephritis, whereas the same dosage administered subcutaneously was effective (3). Although cephaloglycin is rapidly excreted, adequate therapeutic response can be attained orally with multiple doses. Cephaloglycin at 100 mg/kg orally twice daily cured 65% and reduced the kidney counts by 4 log10 or greater in 82% of the E. coli-infected rats (Fig. 1) . The same dose regimen cured 50% and reduced the kidney count by 4 log10 or greater in 55% of the P. mirabilis-infected rats (Fig. 2) .
Twice daily oral treatments of cinoxacin at 12-h intervals using 3, 12, and 50 mg/kg resulted in a dose response with both E. coli and P. mirabilis using the 4-log10 parameter ( Table 2 ).
The effectiveness of cinoxacin was compared with nalidixic acid and oxolinic acid when all three agents were administered in four oral doses daily at 3 mg/kg for 6 days (Fig. 3) . Cinoxacin was six times more effective than oxolinic acid and greater than three times more effective than nalidixic acid in curing E. coliinfected rats. Cinoxacin was four times more effective than either nalidixic acid or oxolinic acid in curing the 'P. mirabilis infection. Four daily treatments with cinoxacin resulted in 100%o 4-loglo titer reductions in the P. mirabilis infection, whereas only 27% of the nalidixic acid-treated and 18% of the oxolinic acidtreated rats were reduced. Rat urine levels of activity for five antimicrobial agents were determined after one oral dose of 3 mg/kg (Fig. 4) . Cinoxacin rapidly reached a concentration of 247 ;ig/ml in the urine. At least 2.5 times more cinoxacin was recovered 2 to 6 h post-treatment than with any outstanding effectiveness achieved with low doses. The detection of demonstrable serum activity with a high recovery of cinoxacin activity in urine shows that cinoxacin possesses highly desirable properties of an effective chemotherapeutic agent for urinary tract infections.
